Trial Condition(s):

Magnetic Resonance Imaging, Liver neoplasms

MRI study to evaluate 0.025 mmol/kg BW Gd-EOB-DTPA (SH L 569 B) and 0.05 mmol/kg BW Gd-BOPTA (Gadobenate Dimeglumine) in patients with known or suspected focal liver lesions

Bayer Identifier:

91106

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

Study Completed

Trial Purpose

Please see attached Study Results Summary below.

Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
No Exclusion Criteria Available

Trial Summary

Enrollment Goal
298
Trial Dates
black-arrow
Phase
3
Could I receive a placebo?
No
Products
Eovist/Primovist (Gadoxetate disodium, BAY86-4873)
Accepts Healthy Volunteers
N/A

Where to Participate

Locations
Status
LocationsStatus

Trial Design